COVID-19 vaccine effectiveness
(Randomized evidence)
Analyses are updated every Friday
Variants of concern
Vaccine types
Overall results (Last update:2021-10-22)
- Forest plots (last update: 2021-10-21)
- Studies included
- Forest plots (last update: 2021-10-15)
- Studies included
- Forest plots (last update: 2021-10-21)
- Studies included
- Forest plots (last update: 2021-10-21)
- Studies included
- BNT/ChA-28 vs BNT/BNT-28 - Forest plots (last update: 2021-08-11)
- BNT162b2 primed with ChAdOx1-S vs No vaccine - Forest plots (last update: 2021-08-11)
- ChAd/BNT-28 vs ChAd/ChAd-28 - Forest plots (last update: 2021-08-11)
RNA based vaccine
Non replicating viral vector
Inactivated virus
Protein subunit
Heterologous
| Trial | Type | Comparisons | Design | Participants | Sample size | Overall risk of bias Highest assessment |
Full description | |
|---|---|---|---|---|---|---|---|---|
| Intervention 1 | Intervention 2 | |||||||
|
NCT04510207, ChiCTR2000034780 Sinopharm - China National Biotec Group Company Limited Al Kaabi N, JAMA, 2021 Full text Commentary Commentary |
Inactivated virus |
WIV04 HBO2 |
Placebo |
RCTPhase 3 | Healthy adults free of known COVID-19 or HIV infection at 3 centres in United Arab Emirates and Bahrain | N=40411 |
Some concerns Details |
|
|
NCT04651790 Sinovac Research and Development Co., Ltd Bueno S, Clin Infect Dis, 2021 Full text Commentary Commentary |
Inactivated virus |
CoronaVac |
Placebo |
RCTPhase 3 | Adult healthcare workers with no history of confirmed symptomatic SARS-CoV-2 infection who were in contact with possible or confirmed cases of COVID-19 in 8 sites in Chile. | N=434 |
Some concerns Details |
|
|
NCT04412538 Institute of Medical Biology (IMB), Chinese Academy of Medical Sciences (CAMS). Che Y, Clin Infect Dis, 2020 Full text Commentary |
Inactivated virus |
KMS-1 100 EU D0/14 KMS-1 150 EU D0/14 KMS-1 100 EU D0/28 KMS-1 150 EU D0/28 |
Placebo |
RCTPhase 2 | Healthy SARS-CoV-2 serology/DNA negative adults in two centres in China | N=750 |
Some concerns Details |
|
|
NCT04641481 Bharat Biotech Ella R, medRxiv, 2021 Full text Commentary Commentary |
Inactivated virus |
BBV152 |
Placebo |
RCTPhase 3 | Adults with no history of SARS-CoV-2 infection who were healthy or had stable chronic medical conditions at 25 centers in India | N=25778 |
Some concerns Details |
|
|
NCT04471519 Bharat Biotech Ella R, Lancet Infect Dis, 2021 Full text Commentary ; Commentary |
Inactivated virus |
BBV152 |
3mcg BBV152 + Algel-IMDG |
RCTPhase 2 | Healthy adults (<65 yo) and children (≥12 yo)volunteers, SARS-CoV-2 infection-free in 9 centres in India | N=380 |
Some concerns Details |
|
|
NCT04471519 Bharat Biotech Ella R, Lancet Infect Dis, 2021 Full text Commentary |
Inactivated virus |
BBV152 3mcg + Algel-IMDG BBV152 BBV152 |
Placebo |
RCTPhase 1 | Healthy SARS-CoV-2 serology/PCR negative adults in 11 centres in India | N=375 |
Low Details |
|
|
ChiCTR2100041705, ChiCTR2100041706 Sinopharm + China National Biotec Group + Beijing Institute of Biological Products Feng Y, medRxiv, 2021 Full text Commentary Commentary |
Inactivated virus |
BBIBP-CorV D0/14 BBIBP-CorV D0/21 |
BBIBP-CorV D0/28 |
RCT* | Healthy adults from high-risk occupational population at a single center in China | N=809 |
Some concerns Details |
|
|
ChiCTR2000031809 Sinopharm + China National Biotec Group Co + Wuhan Institute of Biological Products Guo W, EClinicalMedicine, 2021 Full text Commentary |
Inactivated virus |
Inactivate2.5mcg D0/28/56 Inactivate 5mcg D0/28/56 Inactivate10mcg D0/28/56 Inactivated 5 mcg D0/14 Inactivate 5 mcg D0/21 Inactivate 5 mcg D0/28 Inactivate2.5mcg D0/28/56 |
Placebo Placebo Placebo Placebo Placebo Placebo Placebo |
RCTPhase 1-2 | Healthy adults with no history of COVID-19 at 5 centers in China. | N=1120 |
Some concerns Details |
|
|
NCT04551547 Sinovac Research and Development Co., Ltd Han B, SSRN, 2021 Full text Commentary Commentary |
Inactivated virus |
CoronaVac 1.5 mcg D0/28 Placebo |
CoronaVac |
RCTPhase 1/2 | Healthy children and adolescents aged 3-17 years with no history of SARS-CoV-2 infection in a single centre in China. | N=552 |
Low Details |
|
|
NCT04671017; ISRCTN 82411169 Valneva Austria GmbH + National Institute for Health Research, UK Lazarus R, medRxiv, 2021 Full text Commentary Commentary |
Inactivated virus |
VL A2001 3AU VL A2001 3AU |
VL A2001 35AU VL A2001 7AU |
RCTPhase 1-2 | Healthy adult volunteers aged 18-55 at 4 centers in the UK | N=153 |
Some concerns Details |
|
|
NCT04383574 Sinovac Research and Development Co., Ltd. Li M, medRxiv, 2021 Full text Commentary Commentary |
Inactivated virus |
CoronaVac CoronaVac 1.5 mcg |
Placebo |
RCTPhase 2 | Healthy adults aged ≥60 years with no known history of COVID-19 or recent exposure in a single center in China. | N=350 |
Some concerns Details |
|
|
NCT04456595 Sinovac Research and Development Co., Ltd Palacios R, SSRN, 2021 PROFISCOV Full text Commentary |
Inactivated virus |
CoronaVac |
Placebo |
RCTPhase 3 | Healthcare professionals with or without previous COVID-19 infection caring for COVID-19 patients at 16 centers in Brazil. | N=12408 |
Some concerns Details |
|
|
NCT04756323, ChiCTR2000039462 Shenzhen Kangtai Biological Products and Beijing Minhai Biotechnology Pan HX, Chin Med J, 2021 Full text Commentary |
Inactivated virus |
KCONVAC 5mcg D0/14 KCONVAC 5mcg D0/14 KCONVAC 5mcg D0/28 KCONVAC 5mcg D0/28 KCONVAC 5mcg D0/14 KCONVAC 10mcg D0/14 |
KCONVAC 10mcg D0/14 KCONVAC 5mcg D0/14 KCONVAC 10mcg D0/28 Placebo Placebo Placebo |
RCTPhase 2 | Healthy adult volunteers with no history of COVID-19 and HIV- and SARS-CoV-2 infection-free in a single centre in China. | N=500 |
Low Details |
|
|
NCT04758273, ChiCTR2000038804 Shenzhen Kangtai Biological Products and Beijing Minhai Biotechnology Pan HX, Chin Med J, 2021 Full text Commentary |
Inactivated virus |
5mcg KCONVAC |
10mcg KCONVAC |
RCTPhase 1 | Healthy adult volunteers with no history of COVID-19 and HIV- and SARS-CoV-2 infection-free in a single centre in China. | N=60 |
Low Details |
|
|
NCT04764422 The Government Pharmaceutical Organization (GPO); PATH; Dynavax Pitisuttithum P, medRxiv, 2021 Full text Commentary Commentary |
Inactivated virus |
NDV-HXP-S 1mcg NDV-HXP-S 1mcg + CpG1018 NDV-HXP-S 3mcg NDV-HXP-S 3mcg + CpG1018 NDV-HXP-S 10mcg |
Placebo |
RCTPhase 1 | Healthy adults without immunosuppression negative for SARS-CoV-2 antibodies at a single center in Thailand | N=210 |
Some concerns Details |
|
|
NCT04412538 The Institute of Medical Biology (IMB), Chinese Academy of Medical Sciences (CAM Pu J, Vaccine, 2021 Full text Commentary |
Inactivated virus |
KMS-1 100 EU D0/14 KMS-1 100 EU D0/28 |
Placebo |
RCTPhase 1 | Healthy adults aged 18 to 59 years, SARS-CoV-2 nucleic acid or antibodies negative in a single centre in China | N=192 |
Some concerns Details |
|
|
NCT04582344 Sinovac Research and Development Co., Ltd Tanriover M, Lancet , 2021 Full text Commentary Commentary |
Inactivated virus |
CoronaVac |
Placebo |
RCTPhase 3 | Healthy healthcare workers and adults aged 18–59 years with no history of COVID-19 from 24 centres in Turkey | N=10218 |
Some concerns Details |
|
|
NCT04383574 Sinovac Research and Development Co., Ltd Wu Z, Lancet Infect Dis, 2021 Full text Commentary ; Commentary |
Inactivated virus |
CoronaVac 1.5mcg D0/28 CoronaVac CoronaVac 6mcg D0/28 |
Placebo |
RCTPhase 1/2 | Healthy adults aged 60 years and older with no history of SARS-CoV-2 infection in a single centre in China | N=422 |
Low Details |
|
|
ChiCTR2000031809 Wuhan Institute of Biological Products Co Ltd./Sinopharm Xia S, JAMA, 2020 Full text Commentary |
Inactivated virus |
Inactivated 2.5mcg-3doses Inactivated 5mcg-3doses Inactivated 10mcg-3doses |
Placebo |
RCTPhase 1 | Healthy adults, aged 18 to 59 years, without history ofSARS-CoV(via on-site inquiry) or SARS-CoV-2 infection (via serologicaland nucleic acid test | N=96 |
Low Details |
|
|
ChiCTR2000031809 Wuhan Institute of Biological Products Co Ltd./Sinopharm Xia S, JAMA, 2020 Updated Full text Commentary |
Inactivated virus |
Inactivated 5mcg-D0/14 Inactivated 5mcg-D0/21 |
Placebo |
RCTPhase 2 | Healthy adults, aged 18 to 59 years, without history ofSARS-CoV(via on-site inquiry) or SARS-CoV-2 infection (via serologicaland nucleic acid test | N=224 |
Low Details |
|
|
ChiCTR2000032459 Beijing Institute of Biological Products/Sinopharm Xia S, Lancet Infect Dis, 2020 Full text Commentary |
Inactivated virus |
BBIBP-CorV 8mcg once BBIBP-CorV 4mcg D0/14 BBIBP-CorV 4mcg D0/21 BBIBP-CorV 4mcg D0/28 |
Placebo |
RCTPhase 2 | Healthy SARS-CoV-2 serology negative adults 18-59 years old and ≥60 years old in a single centre in China | N=448 |
Some concerns Details |
|
|
ChiCTR2000032459 Sinopharm + China Biotec Group Co + Beijing Istitute of Biological Products Xia S , Lancet, 2021 New Full text Commentary |
Inactivated virus |
BBIBP-CorV 2 mcg BBIBP-CorV 4 mcg BBIBP-CorV 2 mcg |
Adjuvant Adjuvant BBIBP-CorV 2 mcg |
RCTPhase 1-2 | Healthy children and adolescents aged 3 to 17 years free from SARS-CoV-2 infection and antibodies at a single centre in China | N=1008 |
Low Details |
|
|
NCT04530357 Research Institute for Biological Safety Problems, Rep of Kazakhstan Zakarya K, EClinicalMedicine, 2021 Full text (21)00358-8/fulltextCommentary |
Inactivated virus |
QazCovid-in D1/21 |
Placebo |
RCTPhase 1 | Healthy adults with no history of COVID-19 that tested negative for SARS-CoV-2 and HIV virus at a single centre in Kazakhstan. | N=44 |
Some concerns Details |
|
|
NCT04530357 Research Institute for Biological Safety Problems, Rep of Kazakhstan Zakarya K,, EClinicalMedicine, 2021 Full text (21)00358-8/fulltextCommentary |
Inactivated virus |
QazCovid-in D1/21 |
QazCovid-in D1 |
RCTPhase 2 | Healthy adults with no history of COVID-19 that tested negative for SARS-CoV-2 and HIV virus at a single centre in Kazakhstan. | N=200 |
Some concerns Details |
|
|
NCT04352608 Sinovac Research and Development Co., Ltd Zhang Y, Lancet Infect Dis, 2020 Full text Commentary ; Commentary |
Inactivated virus |
CoronaVac CoronaVac 6 mcg D0/14 CoronaVac CoronaVac 6 mcg D0/28 |
Placebo |
RCTPhase 2 | Healthy SARS-CoV-2 serology/DNA negative adults in a single centre in China | N=600 |
Some concerns Details |
|
|
NCT04352608 Sinovac Research and Development Co., Ltd Zhang Y, Lancet Infect Dis, 2020 Full text Commentary ; Commentary |
Inactivated virus |
CoronaVac 6 mcg D0/28 CoronaVac 3 mcg D0/28 CoronaVac 6 mcg D0/14 CoronaVac |
Placebo |
RCTPhase 1 | Healthy SARS-CoV-2 serology/DNA negative adults in a single centre in China | N=144 |
Some concerns Details |
|